# ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients

> **NCT00794443** · PHASE2,PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 692 (actual)

## Conditions studied

- Osteoporosis
- Bone Loss, Age-Related

## Interventions

- **DRUG:** YM529 / ONO-5920

## Key facts

- **NCT ID:** NCT00794443
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 692 (ACTUAL)
- **Last updated:** 2015-05-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00794443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00794443, "ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00794443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*